Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Abiomed (NASDAQ:ABMD) on Friday, setting a price target of $375, which is approximately 5.60% above the present share price of $355.13.
Antalffy expects Abiomed to post earnings per share (EPS) of $1.38 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Abiomed, with an average price target of $367.5.
The analysts price targets range from a high of $425 to a low of $245.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $209.76 million and a net profit of $61.34 million. The company's market cap is $16.05 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 25.1% and a 69.35% success rate.
ABIOMED , Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.